Austar LifesciencesAULSF 48 Return-on-Tangible-Equity is 2.51% as of Dec. 2025, which is 21% above its 10-year median of 2.08. GuruFocus rates AULSF with a GF Score™ of 48/100 and a GF Value™ of $0.03 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 756 Medical Devices & Instruments companies, Austar Lifesciences ranks better than 51.98% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Austar Lifesciences's annualized net income for the quarter that ended in Dec. 2025 was $2.5 Mil. Austar Lifesciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $99.6 Mil. Therefore, Austar Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 2.51%.
The historical rank and industry rank for Austar Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:
AULSF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -15.65 Med: 2.08 Max: 50.64
Current: 4.86
During the past 13 years, Austar Lifesciences's highest Return-on-Tangible-Equity was 50.64%. The lowest was -15.65%. And the median was 2.08%.
AULSF's Return-on-Tangible-Equity is ranked better than 51.98% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs AULSF: 4.86
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Austar Lifesciences Return-on-Tangible-Equity Related Terms
Austar Lifesciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AULSF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Austar Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.51% mean?
Austar Lifesciences (AULSF) has a Return-on-Tangible-Equity of 2.51% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Austar Lifesciences and its competitors. This is 21% above median its historical median of 2.08. According to the industry distribution chart, Austar Lifesciences ranks #363 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 48%.
Is Austar Lifesciences' Return-on-Tangible-Equity too high?
Austar Lifesciences' current Return-on-Tangible-Equity of 2.51% is 21% above median its 10-year median of 2.08. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Austar Lifesciences' value of 2.51% is 38.5% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #363 out of 756 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #363 out of 756 companies for Return-on-Tangible-Equity. This puts Austar Lifesciences in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Austar Lifesciences' value of 2.51% is 38.5% below this benchmark. While the company's 10-year median is 2.08 vs. the industry median of 4.08, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Return-on-Tangible-Equity of 2.51% is 38.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Return-on-Tangible-Equity is 2.51%, which is 21% above median its own 10-year median of 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 33.3% below its estimated fair value. The current Return-on-Tangible-Equity is 2.51%, which is 21% above median its 10-year median of 2.08 and 38.5% below the Medical Devices & Instruments industry median of 4.08. Austar Lifesciences' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Return-on-Tangible-Equity is 2.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 33.3% below its estimated GF Value™ of $0.03.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
Return-on-Tangible-Equity: 2.51% (21% above median its 10-year median of 2.08)
GF Value™: $0.03 vs. price of $0.02 (33.3% below fair value)
Industry Position: 38.5% below the Medical Devices & Instruments median (#363 of 756)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
48GF Score
Get the complete analysis for AULSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
